A world without Vioxx: To COX-2 or not to COX-2?

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 11, 2004, Pages 849-856

  Simon, Lee S ^a   Strand, Vibeke ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACOXIB; PLACEBO; PROSTACYCLIN; PROTON PUMP INHIBITOR; ROFECOXIB; THROMBOXANE A2; UNCLASSIFIED DRUG; VALDECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; EDEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; INHIBITION KINETICS; INTERPERSONAL COMMUNICATION; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW; VASODILATATION;

EID: 8844266054     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.11.849     Document Type: Article

References (18)

1. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528.
2. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47:349-355.
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
4. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89:425-430.
5. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288.
6. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92:411-418.
7. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction (erratum in Arch Intern Med 2002; 162:1858). Arch Intern Med 2002; 162:1111-1115.
8. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162:1099-1104.
9. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359:118-123.
10. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
11. Graham DJ, Campen D, Cheetham C, et al. Risk of acute myocardial infarction and sudden cardiac death associated with use of COX-2 selective and nonselective NSAIDs [abstract]. Presented at the 20th International Conference on Pharmacoepiderniology and Therapeutic Risk Management, Bordeaux, France, August 22-25, 2004.
12. Whelton A, Fort JG, Pumpa JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients (erratum in Am J Ther 2001; 8:220). Am J Ther 2001; 8:85-95.
13. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90:959-963.
14. Sowers JR, White WB, Pitt B, et al for the Celecoxib Rofecoxib Efficacy and Safety in Co-morbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and non-steroidal antiinflammatory therapy on 24-hour blood pressure in hypertensive patients with osteoarthritis and type 2 diabetes mellitus. Arch Intern Med 2005; in press.
15. White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004, 11:244-250.
16. Ott E, Nussmeier NA, Duke PC, et al for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group and the Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:1481-1492.
17. Farkouh ME, Kirshner H, Harrington RA, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364:675-684.
18. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347:2104-2110.